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Background. Understanding the clinical variability of hemo-
globin measurements in epoetin-treated hemodialysis patients is
important, particularly when this therapy is aimed at maintaining
patient hemoglobin levels within a narrow range, such as the 11
to 12 g/dL range recommended in National Kidney Foundation
Kidney Dialysis Outcomes Quality Initiative (NKF-K/DOQI)
guidelines. This study examines hemoglobin variability under
conditions of standard clinical practice in epoetin-treated he-
modialysis patients.
Methods. We studied 987 hemodialysis patients participating
in an observational retrospective study that evaluated anemia
management practices from October 1, 1996 to December 31,
1997 at 11 United States dialysis centers that were randomly
selected from a pool of nearly all United States dialysis facilities.
Each participating facility maintained its own anemia manage-
ment protocols without specific anemia management recommen-
dations or interventions made as part of this study. Hemoglobin
variability was determined by calculating the 1-month and
2- to 6-month rolling average hemoglobin for each patient.
The range of mean hemoglobin values that included the middle
50% (25th to 75th percentile), 80% (10th to 90th percentile),
and 90% (5th to 95th percentile) of values were determined.
The hemoglobin ranges that included 1 standard deviation (SD)
(67%) of the study values and 2 SD (95%) of the study values
for each time period were calculated.
Results. The mean hemoglobin was between 10.9 and 11.2 g/dL
throughout the study. The hemoglobin range encompassing
50%, 80%, and 90% of values from a single month was 1.7,
3.3, and 4.4 g/dL, respectively. A progressive narrowing in the
range of hemoglobin values encompassed by each percentile
grouping (i.e., hemoglobin variability) was observed as longer
rolling intervals were averaged. The hemoglobin range within
the 25th to 75th percentile was 1.7 g/dL using single-month
hemoglobin values and 1.1 g/dL using a 6-month rolling aver-
age. The range of hemoglobin values that encompassed 90%
of patients was 4.4 g/dL using single-month values, 3.7 g/dL
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using 3-month rolling averages, and 3.2 g/dL using 6-month
rolling averages. Fewer than 50% of patients had hemoglobin
values within the 1.0 g/dL NKF-K/DOQI recommended range,
even when a 6-month rolling average was applied. When hemo-
globin values were measured for 1 month, 1 SD was 1.4 g/dL;
for the 3-month rolling average, 1 SD was 1.1 g/dL; and for
the 4-, 5-, and 6-month rolling averages, 1 SD was 1.0 g/dL.
Greater hemoglobin variability correlated with higher mean
corpuscular hemoglobin (P  0.003) and serum ferritin (P 
0.047), and inversely correlated with age (P 0.006) and serum
albumin (P  0.0001).
Conclusion. Substantial variability occurs in hemoglobin val-
ues in epoetin-treated hemodialysis patients. The NKF-K/
DOQI recommended hemoglobin range appears to be too nar-
row in clinical practice. Expanding the target range and use of
rolling average hemoglobin intervals of 3 to 6 months as a
clinical and quality assurance measure avoids clinical variability
inherent with the use of isolated hemoglobin values or single-
month hemoglobin averages.
Anemia is a common complication in patients with end-
stage renal disease (ESRD) treated with chronic mainte-
nance hemodialysis. In hemodialysis patients, the treatment
of anemia with epoetin [recombinant human erythropoi-
etin (rHuEPO)] improves physiologic and quality-of-life
measures, and higher hematocrit and hemoglobin levels
are associated with lower mortality and hospitalization and
serve as an important indicator of quality of care [1–6]. In
1997, the National Kidney Foundation Dialysis Outcomes
Quality Initiative (NKF-DOQI) [7] recommended guide-
lines for hematocrit and hemoglobin targets of 33% to
36% and 11 to 12 g/dL, respectively, in patients with
chronic kidney disease, including those on dialysis. Since
then, payors, networks, and corporate dialysis providers
have challenged nephrologists caring for dialysis patients
to maintain the hemoglobin or hematocrit of their patients
within these or other similar ranges, which have been sup-
ported more recently in other clinical practice guidelines,
including the updated NKF Kidney Disease Outcomes
Quality Initiative (NKF-K/DOQI) guidelines [8–10].
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In dialysis facilities, hemoglobin or hematocrit are typ-
ically measured frequently, anywhere from weekly to
monthly, leading to adjustments in the dose of epoetin,
often on the basis of standing anemia management proto-
cols, to maintain these values within some desired range.
Hemoglobin has been recommended as the preferred mea-
sure for anemia management [8]. There has been some
concern that the recommended hemoglobin range of 11
to 12 g/dL may be too narrow for routine clinical practice.
Understanding the normal clinical variability of hemo-
globin measurements is therefore critical to optimal clini-
cal management aimed at maintaining patient hemoglobin
levels within this (or any) range. In addition to laboratory
variation, which is reported to be less with hemoglobin
than hematocrit [8, 11], week-to-week and month-to-month
variability in hemoglobin levels may be related to epoe-
tin dose adjustments, route of epoetin administration
[12], variation in hydration status [13], inflammatory pro-
cesses [14], administration of intravenous iron and cor-
rection of iron deficiency, blood loss such as that due to
access surgery, dialysis adequacy [15], and even seasonal
influences [16].
Unfortunately, little is known about the clinical vari-
ability of hemoglobin measurements in hemodialysis pa-
tients. The study reported here examines hemoglobin
variability under conditions of standard clinical practice
in hemodialysis patients.
METHODS
The Anemia Management Practices (AMP) study was
an observational retrospective study with a historical pro-
spective design (i.e., a simulation of a prospective trial,
but with all events occurring at a prior time), designed
primarily to assess the impact of the 1997 Health Care
Financing Administration (HCFA) Hematocrit Manage-
ment Audit (HMA) program. The study monitored ane-
mia management practices at 11 United States dialysis
centers from October 1, 1996 to December 31, 1997.
To ensure that participating dialysis centers reflected a
variety of geographic areas and included not-for-profit,
for-profit, privately owned, corporate-chain owned, univer-
sity-affiliated, free-standing, and hospital-affiliated facili-
ties, and to ensure that a case mix of patients was included
that would capture differences in anemia management
between various dialysis centers, hemoglobin data from
dialysis facilities that participated in the Amgen Optional
Hematocrit Incentive Program, which is virtually all dial-
ysis units in the United States, were screened. From this
group of dialysis facilities, 135 dialysis units were identi-
fied as having at least 40 hemodialysis patients receiving
treatment and meeting one of the following criteria: (1)
75% of the patients had hematocrit33% or (2)50%
of the patients had hematocrit33%, based on hemato-
crit data during the month of May 1997, which was the
midpoint of the study period. Forty-eight of the units met
the criteria of having75% of their patients with hemato-
crit 33% (group A) and 87 of these units had 50%
of their patients with hematocrit 33% (group B).
Facilities were pooled by four main geographic regions
in the United States. Nested randomization by region was
performed to ensure that two facilities were selected from
each region, after which the nesting was automatically
removed. The sample size necessary to detect a 4% de-
crease in the percent of patients with a hematocrit of
33% following implementation of the HMA guidelines
with a 95% power at an alpha of 0.01 was 960 patients.
Therefore, random selection of additional facilities with-
out regard to geographic area was continued until the
total number of patients in the selected facilities exceeded
1100. The final selection included 11 dialysis clinics that
participated in this study; six facilities were in group A,
and five facilities were in group B (see Acknowledgments
for a list of participating investigators and centers, and
the location and type of each dialysis facility). By virtue
of the study design, the mean hematocrit was higher in
group A compared to group B. However, the mean and
median hemoglobin values did not differ between these
two groups either at baseline or when analyzed over the
entire duration of the study (data not shown). Since hemo-
globin is preferred to hematocrit as the measure of ane-
mia in dialysis patients [8], the two groups were therefore
combined for the analysis of hemoglobin variability in
the present study.
The patient population included between 50 and 150
hemodialysis patients from each center who met the fol-
lowing inclusion criteria. All patients were over 18 years
old, had been on hemodialysis for 3 months prior to
the start of data collection (October 1, 1996), and were
alive on December 31, 1997. Excluded from the study
were patients who had received red blood cell transfu-
sions within 10 weeks of start of the data collection pe-
riod and patients with hemoglobinopathies, hemochro-
matosis, malignancy, known human immunodeficiency
virus (HIV) infection, or active inflammatory disease or
gastrointestinal bleeding. In larger facilities in which more
than 150 patients would have been eligible for inclusion,
a subgroup of no more than 150 qualified patients was
randomly selected to participate from a list of all eligible
patients within the facility.
Each physician and facility maintained its own anemia
management protocols and policies, and any changes in
anemia management that may have occurred during the
period of interest for this study were at the discretion
of treating nephrologists and facility medical directors.
There were no specific anemia management interven-
tions made as part of this study, no recommendations
for changes in anemia management were suggested by
the study sponsor, and, given the retrospective design of
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this study, study data that might have affected anemia
management at individual facilities were not available
to participants. Laboratory tests were performed at the
usual clinical laboratory for each facility; different hemo-
globin assays may have been used by the various facilities
but did not change during the course of the study at any
facility.
Data parameters
Hemoglobin measurements were taken 1, 2, or 4 times
monthly, according to the clinical practices at each partic-
ipating facility. Hemoglobin variability was determined
by calculating the rolling average hemoglobin for each
patient across different time intervals during the 15
months of the study (averages for intervals of 2, 3, 4, 5,
and 6 months). Using the patients’ mean hemoglobin
values for each interval, the range of mean hemoglobin
values that included the middle 50% (25th to 75th per-
centile), 80% (10th to 90th percentile), and 90% (5th to
95th percentile) of values were determined. In addition,
the hemoglobin ranges that included 1 standard devia-
tion (SD) (67% of the interval’s values) and 2 SD (95%
of the interval’s values) for each time period were calcu-
lated.
To assess what parameters contributed to variability,
the SD of hemoglobin was used as a dependent variable
and demographic, clinical, and laboratory parameters
were evaluated as independent variables. Demographic
variables included age, gender, and race. Clinical vari-
ables included the presence or absence of diabetes melli-
tus, cause of ESRD, time on dialysis, epoetin treatment,
and comorbid conditions present at study entry. Labora-
tory measurements included hemoglobin, hematocrit,
mean corpuscular volume, mean corpuscular hemoglo-
bin, ferritin, transferrin saturation (TSAT), Kt/V, albu-
min, and intact parathyroid hormone (iPTH).
Data collection and statistical methods
Clinical and laboratory data were collected for 987
patients. Data available electronically were obtained in
the format generated by each dialysis center’s computer
system, and integrated into a standard SAS platform. The
remaining data were captured using data entry screens
constructed using Microsoft Access with Visual Basic
customization, and analyses were done using SAS soft-
ware. Stepwise regression with backward elimination was
performed using the 15-month trend for the independent
variables listed above, and frequencies were used for the
categorical data. The final model was obtained after 14
iterative steps and was significant at P  0.0001. Testing
for statistical significance was performed using single-
group or two-group t tests for continuous variables and
McNemar’s chi-square test for categorical variables. Log
transformations were applied to normalize the distribu-
Table 1. Demographic and clinical characteristics
Characteristic (N  987)
Age years 58.215
Gender %
Female 50
Race %
Caucasian 28
African American 64
Other 8
Cause of end-stage renal disease %
Diabetes mellitus 34
Hypertension 39
Glomerulonephritis 11
Cystic kidney disease 2
Other 14
Years on dialysis 3.63.8
Years on epoetin 2.51.9
DataSD if indicated.
tion of skewed data (epoetin dose, serum ferritin, and
iPTH).
RESULTS
Demographic characteristics of the study population
are summarized in Table 1. Mean values for key labora-
tory parameters during each 3-month period throughout
the duration of the study (beginning the first calendar
quarter of 1996 through the fourth quarter of 1997) along
with mean administered epoetin doses are presented in
Table 2. In each quarter, between 94% and 96% of
patients received epoetin and between 65% and 79% of
patients received intravenous iron. Of factors that might
have affected hemoglobin levels, only serum ferritin lev-
els, which increased, changed consistently over the dura-
tion of the study. Mean epoetin doses varied and were
significantly different from baseline in only two of the
subsequent four study periods. There was not a consis-
tent change or trend for TSAT, serum albumin, or Kt/V.
While iPTH levels tended to fall, this did not reach statis-
tical significance. The mean hemoglobin ranged between
10.9 and 11.2 g/dL throughout the study. The 25th to
75th, 10th to 90th, and 5th to 95th percentile hemoglobin
ranges for the 1-month and 2- through 6-month rolling
averages are provided in Table 3.
The hemoglobin range encompassing 50%, 80%, and
90% of values from a single month was 1.7, 3.3, and 4.4
g/dL, respectively. As expected, a progressive narrowing
in the range of hemoglobin values encompassed by each
percentile grouping (i.e., hemoglobin variability) was ob-
served as longer rolling intervals were averaged. For
instance, the hemoglobin range within the 25th to 75th
percentile grouping continued to narrow with increasing
rolling average intervals, from 1.7 g/dL using single-month
hemoglobin values, down to 1.1 g/dL using a 6-month
rolling average. The range of hemoglobin values that
encompassed 90% of patients was 4.4 g/dL using single-
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Table 2. Quarterly means for various anemia management-related laboratory values and epoetin doses administered for entire study
population (N  987) throughout 15-month study period, beginning the fourth calendar quarter of 1996 (Q4-96)
and ending the fourth quarter of 1997 (Q4-97)
Parameter Q4-96 Q1-97 Q2-97 Q3-97 Q4-97
Hematocrit % 33.8 (3.4) 34.3 (3.8) 34.4 (3.4) 33.9 (3.3) 33.6 (3.4)
Hemoglobin g/dL 11.1 (1.2) 11.2 (1.2) 11.2 (1.2) 11.0 (1.1) 10.9 (1.1)
Mean corpuscular hemoglobin pg/dL 29.9 (2.9) 29.9 (2.8) 30.1 (4.2) 30.2 (5.8) 30.0 (2.8)
Mean corpuscular volume fl 90.7 (7.1) 91.5 (7.4) 92.1 (7.5) 92.4 (7.4) 91.9 (7.1)
Ferritin ng/mL 385 (421) 495 (504) 539 (509) 609 (513) 611 (501)
Transferrin saturation % 29.8 (14.6) 29.4 (12.7) 32.4 (14.3) 31.8 (14.1) 30.7 (13.1)
Albumin g/dL 3.8 (0.4) 3.9 (0.4) 3.9 (0.3) 3.9 (0.4) 3.9 (0.4)
Intact parathyroid hormone pg/dL 313 (376) 354 (437) 306 (354) 237 (277) 275 (426)
Kt/V 1.45 (0.31) 1.51 (0.68) 1.47 (0.29) 1.49 (0.27) 1.51 (0.28)
Epoetin dose U/week 13090 (8134) 12335 (8210) 11884 (8506) 12478 (9109) 11996 (8827)
Data shown asSE in parenthesis.
Table 3. Hemoglobin range, expressed as both width of the range and actual hemoglobin range, encompassing specified percentages of
patient’s hemoglobin values for 1-month values and rolling averages of 2 to 6 months
25th–75th percentile 10th–90th percentile 5th–95th percentile
(50% of patients) (80% of patients) (90% of patients)
Rolling average interval g/dL g/dL g/dL
One month 1.7 (10.3–12.0) 3.3 (9.4–12.7) 4.4 (8.8–13.2)
Two-month rolling average 1.4 (10.4–11.8) 3.0 (9.5–12.5) 3.9 (9.0–12.9)
Three-month rolling average 1.3 (10.5–11.8) 2.7 (9.7–12.4) 3.7 (9.1–12.8)
Four-month rolling average 1.3 (10.5–11.8) 2.5 (9.8–12.3) 3.4 (9.3–12.7)
Five-month rolling average 1.2 (10.5–11.7) 2.3 (9.9–12.2) 3.2 (9.4–12.6)
Six-month rolling average 1.1 (10.6–11.7) 2.3 (9.9–12.2) 3.2 (9.4–12.6)
Fig. 1. Width of hemoglobin (Hgb) range encompassing specified per-
centages and percentile groups of patient’s hemoglobin values for 1-month
values and rolling averages of 2 to 6 months.
month values, 3.7 g/dL using 3-month rolling averages,
and 3.2 g/dL using 6-month rolling averages. The hemo-
globin ranges that encompassed 50%, 80%, and 90% of
patients over periods of 1 to 6 months with rolling aver-
ages are also shown in Figure 1. Fewer than 50% of pa-
tients had hemoglobin ranges within the recommended
NKF-DOQI guidelines of 1.0 g/dL, in place at the time
of this study, even when a 6-month rolling average was
applied.
By analysis of aggregate SD data, it was determined
Table 4. Width of hemoglobin range encompassing 1 SD and
specified percentages of patient’s hemoglobin values for 1-month
values and rolling averages of 2 to 6 months
Range width Range width
1 SD for 67% of for 95% of
Range g/dL patients g/dL patients g/dL
One month 1.4 2.8 5.6
Two-month rolling average 1.2 2.4 4.8
Three-month rolling average 1.1 2.2 4.4
Four- to six-month rolling
average 1.0 2.0 4.0
that when hemoglobin values were measured for 1 month,
1 SD was 1.4 g/dL so that approximately 67% of values
were included in a 2.8 g/dL range and 95% of values
were included in a 5.6 g/dL range. For the 3-month rolling
average, 1 SD was 1.1 g/dL with a 2.2 g/dL and 4.4 g/dL
range that included 67% and 95% of values, respectively.
For the 4-, 5-, and 6-month rolling averages, 1 SD was
1.0 g/dL with a 2.0 g/dL and 4.0 g/dL range that included
67% and 95% of values, respectively (Table 4).
Greater hemoglobin variability was significantly corre-
lated with higher mean corpuscular hemoglobin (P 
0.003) and serum ferritin (P  0.047), and inversely cor-
related with age (P  0.006) and serum albumin (P 
0.0001). A decline in albumin of 1 g/dL correlated with
an increase in SD of 0.3 g/dL. A 100 ng/mL increase in
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Table 5. Regression analysis
Parameter Estimate F value P value
Albumin 0.289 17.2 0.0001
Mean corpuscular hormone 0.025 9.2 0.003
Age 0.004 7.7 0.006
Ferritin 0.0001 4.0 0.047
serum ferritin was associated with a 0.01 ng/mL increase
in SD. For each additional 5 years of age, the SD nar-
rowed by 0.02 g/dL (Table 5). Other demographic and
clinical variables, including epoetin dose, and other labo-
ratory parameters, including Kt/V and iPTH, levels, were
not significantly correlated with increased hemoglobin
variability.
DISCUSSION
Anemia management has become a major focus of
the care of hemodialysis patients as a result of the avail-
ability of epoetin therapy and evidence linking clinical
outcomes to hemoglobin and Hct levels [1–6]. Specific
target hematocrit or hemoglobin ranges have been rec-
ommended by the NKF-DOQI guidelines [7], the subse-
quent NKF-K/DOQI guidelines [8] and guidelines from
the European and Canadian renal communities [9, 10].
The hemoglobin target of 11 to 12 g/dL, as recommended
by the NKF-K/DOQI guidelines [8], has become well
accepted in the United States. Hemoglobin, now pre-
ferred to hematocrit as the measure of anemia [8], is
typically measured on a weekly to monthly basis, with
changes in epoetin dosing made accordingly, often driven
by standing anemia management protocols.
In clinical practice it is often difficult to maintain hemo-
globin levels within such a narrow range due to substan-
tial inter- and intrapatient variability. Our findings show
that large variability occurs in hemoglobin values among
hemodialysis patients. The wide variability in hemoglo-
bin among hemodialysis patients is likely a consequence
of frequent adjustments of epoetin doses, withholding
doses when certain hemoglobin targets are exceeded, vari-
ability in route of administration [12] and response to
epoetin [17, 18], iron deficiency, the hematopoietic re-
sponse to iron therapy, surgery-related blood loss, inflam-
matory or infectious disease processes [14, 19–21], hyper-
parathyroidism [21–23], dialysis adequacy [15, 24, 25],
and laboratory variation and error. Interdialytic weight
gains also affect measured hemoglobin values [13]. Sea-
sonal fluctuations in hemoglobin and other clinical and
laboratory parameters have also been reported [16].
Lacson, Ofsthun, and Lazarus [26] recently published
a detailed analysis of hemoglobin variability among he-
modialysis and peritoneal dialysis patients from a single
dialysis chain (Fresenius Medical Care North America).
In the first quarter of 2000, only 38.4% of patients had
mean 3-month rolling average hemoglobin values within
the range of 11 to 12 g/dL, with an average intrapatient
hemoglobin SD of 1.3 mg/dL. These authors evaluated
intrapatient variability based on 3-month rolling average
hemoglobin levels over the course of a year, demonstrating
that there was a broad distribution of SD for this average.
The median and 75th percentile intrapatient SD were
0.7 g/dL and 1.0 g/dL, respectively, with a range of
0.1 to 2.5 g/dL. Thus, a patient with the median SD would
have a 1.4 g/dL fluctuation in 3-month rolling average
hemoglobin over the course of a year. Based on these
SDs, the authors concluded that a patient from their
cohort with hemoglobin measured twice monthly and a
3-month rolling average hemoglobin of 11.5 g/dL would
have 42% of samples outside the range of 11 to 12 g/dL
based on the median SD and 58% of samples outside
this range based on the 75th percentile SD.
Hemoglobin or hematocrit variability in hemodialysis
patients has also been the subject of two other prelimi-
nary reports recently. Freund and Nielsen evaluated he-
matocrit values from 680 hemodialysis patients with 10
or more results measured at a commercial laboratory
[abstract; Freund LE et al, J Am Soc Nephrol 11:1401A,
2000]. Individual patient hematocrit value SDs were nor-
mally distributed, ranging from 0.5 to 7.5, reflecting the
highly variable nature of hematocrit in this population.
The authors noted that a patient with an overall hemato-
crit average of 33% and average SD of 2.94 would be
expected to have a hematocrit above 36% in about 10%
of the monthly samples. More recently, Brier et al ana-
lyzed data from the Renal Network Data System for
patients from dialysis facilities in Illinois, Indiana, Ken-
tucky, and Ohio, for the last 3 months of 1999 [abstract;
Brier ME et al, J Am Soc Nephrol 13:628A, 2002]. Using
3-month averages, only 66% of patients were maintained
within the 11 to 12 g/dL target range. These authors calcu-
lated that a hemoglobin range of 11.0 to 12.24 g/dL would
encompass 75% of patients, a range of 11.0 to 12.96 g/dL
would encompass 90% of patients, and a range of 11.0
to 13.96 g/dL would encompass 95% of patients, and sug-
gested that the anemia goal should be modified to account
for clinical variability.
Data from our 15-month study indicates that 1-month
hemoglobin values exhibit the greatest degree of vari-
ability; a 3.3 g/dL range included only 80% of patients
and a 4.4 g/dL range would be needed to include 90%
of patients. Increasing the length of the hemoglobin mon-
itoring period reduces this variability and narrows the
hemoglobin range that encompasses the various percen-
tile fractions of the entire hemodialysis patient popula-
tion. Use of the 3-month rolling average, as is currently
the practice for claims review by Centers for Medicare
and Medicaid Services (CMS), is associated with less
variability than 1-month values. Nonetheless, even for
3-month rolling averages, a 2.7 g/dL range would include
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80% of hemoglobin values. However, extending the
monitoring period to 5 or 6 months reduces the range
that encompasses 80% of the values to 2.3 g/dL.
Parameters identified as being correlated with increased
hemoglobin variability included lower serum albumin,
higher serum ferritin and mean corpuscular hemoglobin,
and age (younger patients had higher variability, com-
pared with older patients). The correlations with serum
albumin and ferritin may reflect the effects of infection
and inflammation on albumin and ferritin levels and eryth-
ropoiesis. The reason for an association between advanced
age and narrower hemoglobin variability is unclear.
There are some limitations to our study that should
be considered. First, our data were collected in 1996 and
1997, just prior to and during implementation of the now
repealed HCFA HMA program, so changes in anemia
management practices or targets during this period and
since then may have affected hemoglobin variability.
Anemia management practices may also have changed
during the period of our study in response to the NKF-
DOQI guidelines (subsequently renamed the NKF-K/
DOQI guidelines), which were published in 1997 [7], but
were previously presented at national meetings in 1996.
In fact, however, the percentage of patients with hemato-
crit or hemoglobin values within the NKF-K/DOQI
range reported in our study and several subsequent re-
ports from other sources are quite similar [26–29]. In
the most recently published United States Renal Data
System (USRDS) annual report, approximately two thirds
of patients (i.e., those which would encompass 1 SD around
the mean) had 1-month hematocrit values of 30% to
37.5%, corresponding to a hemoglobin range of approxi-
mately 2.5 g/dL, which is remarkably similar to the value
of 2.8 g/dL we observed. Another concern is that if the
upper limits of the hemoglobin target range applied in
practice has increased since our study was initiated, as
is suggested by a trend toward greater numbers of pa-
tients with hemoglobin levels 12 g/dL since 1997 [29],
this may impact on overall hemoglobin variability. A
report from Richardson, Bartlett, and Will [30] would
suggest that anemia management practices aimed at
higher hemoglobin targets is likely to be associated with
increased hemoglobin variability. Comparing a protocol
with a ceiling value of 13 g/dL and another with a ceiling
value of 12 g/dL (above which epoetin doses were de-
creased), the SD (1-month averages) was higher for the
group whose ceiling for epoetin therapy was 13 g/dL (2.07)
versus the group whose ceiling was 12 g/dL (1.37) [30].
In contrast, Lacson, Ofsthun, and Lazarus [26] found
that despite an increase in mean hemoglobin levels be-
tween 1995 and 2000, overall hemoglobin variability as
measured by the population SD around the mean, re-
mained steady at 1.3 to 1.5 g/dL. Also, in a summary
of annual data from the ESRD Clinical Performance
Measures Project, Wish [31] showed that, although the
mean hemoglobin and percent of patients with hemoglo-
bin 11 g/dL increased between 1997 and 2001, the he-
moglobin SD varied only between 1.22 and 1.29 without
a consistent trend during this period.
Our study included a small sample of the entire United
States dialysis population, and it is possible that in a
much larger sample less hemoglobin variability would be
encountered. Nonetheless, our findings are consistent with
those in reports described above and elsewhere [27–29].
The percentage of patients in our study who were Afri-
can American was about twice that in the United States
dialysis population at the time our study was done [32].
Ours was not a random sample of the entire United States
hemodialysis population and the demographic character-
istics of our study likely reflect features of the study
design (i.e., excluding units with fewer than 40 patients)
and location of participating centers (i.e., urban and larger
metropolitan areas). Race, however, was not correlated
with hemoglobin variability in our analysis. Finally, given
the nature of our study, detailed information about the
specific anemia management practices at each dialysis
facility, such as epoetin and iron dosing protocols, and
assessment of the contribution to hemoglobin assay vari-
ability on our overall findings are not available. In the
study of Lacson, Ofsthun, and Lazarus [26], though, hemo-
globin interassay variability amounted to a SD effect of
only 0.11 to 0.16 g/dL at a hemoglobin level of 12 g/dL
and the effect of hemoglobin testing variability on overall
hemoglobin variability was suggested to be less than 0.3
g/dL for a 3-month rolling average.
A major strength of our study is that our analysis of
complete data from nearly 1000 patients is derived from
dialysis facilities across the country of various sizes and
types, rather than from a single for-profit dialysis chain,
region, or network, thus perhaps providing a more wide-
spread view of hemoglobin variability across different
dialysis settings and in response to various anemia man-
agement practices. Although we do not have the ability
to analyze hemoglobin variability related to use of differ-
ent hemoglobin assays among centers in our study, the
fact that our data are derived from a variety of clinical
laboratories using various hemoglobin assays should en-
hance the generalizability of our findings to the broad
population of hemodialysis patients. Another strength
of our study is that our analysis was confined to hemodi-
alysis patients only, evaluated hemoglobin and other
anemia-related parameters over an extended 15-month
period, and analyzed hemoglobin variability using single-
month data as well as rolling averages over periods of
2 to 6 months.
While single-month hemoglobin values are of obvious
importance in the month-to-month monitoring and man-
agement of individual patients, extending the rolling av-
erage hemoglobin interval from 3 to 6 months appears
to provide a more clinically applicable measure of mainte-
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nance anemia management outcomes and avoids clinical
variability inherent with the use of single-month values.
The NKF-K/DOQI recommended hemoglobin range ap-
pears to be too narrow in clinical practice and for quality
assurance and reimbursement purposes. Even if rolling
average periods of 6 months are considered, a 1.1 g/dL
range (similar to the NKF-K/DOQI range) included
fewer than 50% of patients. In our study, a 2- to 3-month
rolling average range of 2.4 g/dL, virtually identical to
that observed in the study of Lacson, Ofsthun, and Laza-
rus [26], encompassed over 67% of patients. Use of ex-
tended rolling averages would likely create less urgency
in maintaining patients within a specific hemoglobin
range each month; lessen the impulse to frequently adjust
epoetin doses; and create a broader, more stable, assess-
ment of anemia status. As a quality assurance monitor,
use of 3- to 6-month rolling averages is also likely to
provide assessments that are more meaningful than use
of single-month values. It is not known what if any eco-
nomic impact, either beneficial or detrimental, on payors
or dialysis providers would result from a broadening of
the target hemoglobin range.
There is increasing evidence that there are clinical
benefits to maintaining higher hemoglobin values, even
approaching the normal range [5, 6, 33–36], but there is
also concern about the potential risks of such therapy
[37]. As an alternative to the currently defined narrow
NKF-K/DOQI target range of 11.0 to 12.0 g/dL (hemato-
crit target of 33% to 36%), a more practical approach
that would likely optimize patient care and clinical out-
comes might be to adopt a goal of maintaining all single-
month hemoglobin values11 g/dL (hematocrit33%)
similar to the European Best Practices Guideline recom-
mendation [38] but with use of a 3- or 4-month rolling
average range that encompasses at least 80% of patient
hemoglobin values for quality assurance and anemia pro-
tocol management purposes. Based on our data, this would
necessitate a hemoglobin range of at least 2.5 g/dL. This,
or any other recommended approach, will require appro-
priate testing for clinical outcomes and cost-benefit as-
sessment.
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